Advaxis, Inc. (ADXS)
USD 0.03
(0.0%)
USD 0.03
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 40.99 Million USD | 1680.11% |
| 2022 | 2.3 Million USD | -70.82% |
| 2021 | 7.89 Million USD | -5.44% |
| 2020 | 8.34 Million USD | 49.01% |
| 2019 | 5.6 Million USD | -85.34% |
| 2018 | 38.21 Million USD | -2.96% |
| 2017 | 39.38 Million USD | -20.83% |
| 2016 | 49.74 Million USD | 1141.43% |
| 2015 | 4 Million USD | 45.82% |
| 2014 | 2.74 Million USD | -50.79% |
| 2013 | 5.58 Million USD | -42.9% |
| 2012 | 9.77 Million USD | -45.43% |
| 2011 | 17.92 Million USD | 1.37% |
| 2010 | 17.67 Million USD | -4.17% |
| 2009 | 18.44 Million USD | 749.99% |
| 2008 | 2.17 Million USD | 82.02% |
| 2007 | 1.19 Million USD | -84.53% |
| 2006 | 7.7 Million USD | 568.99% |
| 2005 | 1.15 Million USD | -37.42% |
| 2004 | 1.84 Million USD | 1741.58% |
| 2003 | 100 Thousand USD | 0.0% |
| 2002 | - USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q3 | 13.22 Million USD | 18.67% |
| 2023 Q2 | 11.14 Million USD | -1.57% |
| 2023 Q1 | 11.32 Million USD | 27.65% |
| 2023 FY | 40.99 Million USD | 1680.11% |
| 2023 Q4 | 40.99 Million USD | 210.06% |
| 2022 Q3 | 2.3 Million USD | 20.83% |
| 2022 FY | 2.3 Million USD | -70.82% |
| 2022 Q4 | 8.86 Million USD | 285.06% |
| 2022 Q1 | 2.36 Million USD | -70.22% |
| 2022 Q2 | 1.9 Million USD | -19.48% |
| 2021 Q4 | 7.94 Million USD | 0.72% |
| 2021 Q3 | 7.89 Million USD | 38.17% |
| 2021 Q2 | 5.71 Million USD | -7.86% |
| 2021 FY | 7.89 Million USD | -5.44% |
| 2021 Q1 | 6.19 Million USD | -16.57% |
| 2020 Q2 | 6.31 Million USD | -89.54% |
| 2020 Q4 | 7.43 Million USD | -10.98% |
| 2020 FY | 8.34 Million USD | 49.01% |
| 2020 Q1 | 60.38 Million USD | 978.15% |
| 2020 Q3 | 8.34 Million USD | 32.08% |
| 2019 FY | 5.6 Million USD | -85.34% |
| 2019 Q4 | 5.6 Million USD | -2.18% |
| 2019 Q3 | 5.72 Million USD | -16.58% |
| 2019 Q2 | 6.86 Million USD | 3.98% |
| 2019 Q1 | 6.6 Million USD | -48.44% |
| 2018 Q2 | 27.72 Million USD | -17.76% |
| 2018 FY | 38.21 Million USD | -2.96% |
| 2018 Q1 | 33.71 Million USD | -11.68% |
| 2018 Q3 | 38.21 Million USD | 37.82% |
| 2018 Q4 | 12.8 Million USD | -66.5% |
| 2017 Q2 | 36.36 Million USD | -20.98% |
| 2017 Q1 | 46.01 Million USD | 2.65% |
| 2017 FY | 39.38 Million USD | -20.83% |
| 2017 Q4 | 38.17 Million USD | -3.07% |
| 2017 Q3 | 39.38 Million USD | 8.3% |
| 2016 Q1 | 9.1 Million USD | 20.33% |
| 2016 Q2 | 7.62 Million USD | -16.27% |
| 2016 Q4 | 44.82 Million USD | -9.88% |
| 2016 Q3 | 49.74 Million USD | 552.37% |
| 2016 FY | 49.74 Million USD | 1141.43% |
| 2015 Q3 | 4 Million USD | -16.04% |
| 2015 Q2 | 4.77 Million USD | 10.59% |
| 2015 FY | 4 Million USD | 45.82% |
| 2015 Q4 | 7.56 Million USD | 88.88% |
| 2015 Q1 | 4.31 Million USD | 37.03% |
| 2014 Q1 | 3.36 Million USD | -17.35% |
| 2014 Q3 | 2.74 Million USD | -3.03% |
| 2014 Q2 | 2.83 Million USD | -15.85% |
| 2014 Q4 | 3.14 Million USD | 14.61% |
| 2014 FY | 2.74 Million USD | -50.79% |
| 2013 FY | 5.58 Million USD | -42.9% |
| 2013 Q1 | 10.85 Million USD | -6.82% |
| 2013 Q2 | 11.09 Million USD | 2.13% |
| 2013 Q3 | 5.58 Million USD | -49.65% |
| 2013 Q4 | 4.07 Million USD | -27.03% |
| 2012 Q1 | 15.58 Million USD | -1.99% |
| 2012 Q2 | 9.12 Million USD | -41.45% |
| 2012 Q3 | 9.77 Million USD | 7.19% |
| 2012 Q4 | 11.65 Million USD | 19.18% |
| 2012 FY | 9.77 Million USD | -45.43% |
| 2011 FY | 17.92 Million USD | 1.37% |
| 2011 Q4 | 15.89 Million USD | -11.29% |
| 2011 Q1 | 26.1 Million USD | 81.65% |
| 2011 Q3 | 17.92 Million USD | 5.82% |
| 2011 Q2 | 16.93 Million USD | -35.14% |
| 2010 Q2 | 22.36 Million USD | -6.88% |
| 2010 FY | 17.67 Million USD | -4.17% |
| 2010 Q4 | 14.37 Million USD | -18.69% |
| 2010 Q3 | 17.67 Million USD | -20.94% |
| 2010 Q1 | 24.01 Million USD | 21.28% |
| 2009 Q2 | 15.47 Million USD | 476.57% |
| 2009 Q1 | 2.68 Million USD | 29.28% |
| 2009 Q4 | 19.79 Million USD | 7.33% |
| 2009 Q3 | 18.44 Million USD | 19.23% |
| 2009 FY | 18.44 Million USD | 749.99% |
| 2008 FY | 2.17 Million USD | 82.02% |
| 2008 Q2 | 1.4 Million USD | 11.98% |
| 2008 Q4 | 2.07 Million USD | -4.35% |
| 2008 Q3 | 2.17 Million USD | 54.37% |
| 2008 Q1 | 1.25 Million USD | -8.89% |
| 2007 Q4 | 1.37 Million USD | 15.58% |
| 2007 Q1 | 7.25 Million USD | 12.59% |
| 2007 Q2 | 5.53 Million USD | -23.65% |
| 2007 Q3 | 1.19 Million USD | -78.46% |
| 2007 FY | 1.19 Million USD | -84.53% |
| 2006 Q4 | 6.44 Million USD | -16.45% |
| 2006 Q3 | 7.7 Million USD | 60.02% |
| 2006 Q1 | 4.64 Million USD | 291.26% |
| 2006 Q2 | 4.81 Million USD | 3.64% |
| 2006 FY | 7.7 Million USD | 568.99% |
| 2005 Q2 | 1.08 Million USD | 9.19% |
| 2005 Q4 | 1.18 Million USD | 3.1% |
| 2005 FY | 1.15 Million USD | -37.42% |
| 2005 Q3 | 1.15 Million USD | 6.37% |
| 2005 Q1 | 992.23 Thousand USD | 7.44% |
| 2004 FY | 1.84 Million USD | 1741.58% |
| 2004 Q4 | 923.51 Thousand USD | 0.0% |
| 2003 FY | 100 Thousand USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -149340.455% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -333.09% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 43.431% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -4968.781% |
| Rebus Holdings, Inc. | 5.24 Million USD | -682.068% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 30.532% |
| Qrons Inc. | 1.48 Million USD | -2653.788% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -3243.302% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 45.28% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -91621.854% |
| Skye Bioscience, Inc. | 14.07 Million USD | -191.326% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 23.092% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -327.843% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -9624.647% |
| SQZ Biotechnologies Company | 50.03 Million USD | 18.072% |
| Intellipharmaceutics International Inc. | 12 Million USD | -241.384% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -964.437% |
| Mesoblast Limited | 188.44 Million USD | 78.245% |
| Marizyme, Inc. | 26.67 Million USD | -53.683% |
| Genus plc | 485 Million USD | 91.547% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -601.671% |
| Pharming Group N.V. | 244.07 Million USD | 83.203% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -1939.47% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -1529.199% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -978.842% |
| ContraFect Corporation | 32.53 Million USD | -26.021% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -1969.138% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -971.049% |
| IMV Inc. | 37.93 Million USD | -8.075% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -248.067% |
| MultiCell Technologies, Inc. | 1617.67 USD | -2534162.241% |
| ONE Bio Corp. | 27.49 Million USD | -49.099% |
| Accustem Sciences Inc. | 1.07 Million USD | -3698.603% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 47.045% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -1838.282% |
| Q BioMed Inc. | 8.13 Million USD | -404.074% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 50.569% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -696.652% |
| Biomind Labs Inc. | 1.49 Million USD | -2635.598% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 65.469% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -353.386% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -122.763% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -2759.133% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -28751.121% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -20284.256% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -613.492% |
| GB Sciences, Inc. | 5.41 Million USD | -656.725% |
| Alpha Cognition Inc. | 7.16 Million USD | -472.188% |
| HST Global, Inc. | 593.59 Thousand USD | -6806.416% |
| CSL Limited | 18.62 Billion USD | 99.78% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -3155.736% |
| Halberd Corporation | 728.71 Thousand USD | -5525.762% |
| Enzolytics Inc. | 365.26 Million USD | 88.776% |
| Agentix Corp. | 2.51 Million USD | -1532.946% |
| Resverlogix Corp. | 67.39 Million USD | 39.171% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -4787.855% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 90.786% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -2291.832% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -65.667% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -244.414% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -1018.531% |
| AVAX Technologies, Inc. | 3.99 Million USD | -926.505% |
| Zenith Capital Corp. | 27.56 Thousand USD | -148603.254% |
| Genscript Biotech Corporation | 1.32 Billion USD | 96.908% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -17078.007% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -997.821% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -5921.438% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -1411.852% |
| Kadimastem Ltd | 3.5 Million USD | -1069.688% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -61152.97% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 18.439% |
| BioStem Technologies, Inc. | 15.9 Million USD | -157.761% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -8722.055% |
| LadRx Corporation | 2.2 Million USD | -1763.007% |
| Cell Source, Inc. | 15.8 Million USD | -159.358% |
| Regen BioPharma, Inc. | 5.45 Million USD | -651.17% |
| Regen BioPharma, Inc. | 5.45 Million USD | -651.17% |
| NovAccess Global Inc. | 7.86 Million USD | -421.529% |
| Affymax, Inc. | 8.87 Million USD | -362.135% |
| Itoco Inc. | 1.65 Million USD | -2379.87% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -1898.279% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -577.732% |
| Mobile Lads Corp. | 1.31 Million USD | -3021.134% |
| CytoDyn Inc. | 127.89 Million USD | 67.945% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -97978.901% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -2517.25% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -271.163% |
| SYBLEU INC | 681.41 Thousand USD | -5916.322% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -571.856% |
| International Stem Cell Corporation | 5.27 Million USD | -676.881% |
| Bioxytran, Inc. | 3.24 Million USD | -1161.609% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -6450.881% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -787.912% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -84.128% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -1924.107% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -648.375% |
| Neutra Corp. | 973.52 Thousand USD | -4111.071% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -41.292% |
| PureTech Health plc | 125.58 Million USD | 67.355% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -991.153% |
| IXICO plc | 1.9 Million USD | -2057.353% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -99.698% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 60.323% |
| CSL Limited | 18.62 Billion USD | 99.78% |
| Cellectis S.A. | 249.36 Million USD | 83.56% |